Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Leases: 2022-2024

Historic Operating Leases for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $17.4 million.

  • Taysha Gene Therapies' Operating Leases fell 7.01% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 7.01%. This contributed to the annual value of $17.4 million for FY2024, which is 8.40% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Operating Leases stood at $17.4 million for FY2024, which was down 8.40% from $19.0 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Operating Leases peaked at $20.4 million during FY2022, and registered a low of $17.4 million during FY2024.
  • Moreover, its 3-year median value for Operating Leases was $19.0 million (2023), whereas its average is $18.9 million.
  • Data for Taysha Gene Therapies' Operating Leases shows a maximum YoY decreased of 8.40% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Taysha Gene Therapies' Operating Leases stood at $20.4 million in 2022, then decreased by 7.27% to $19.0 million in 2023, then declined by 8.40% to $17.4 million in 2024.